REVB - יחס חוב להיוון בספרים Revelation Biosciences Inc

Revelation Biosciences develops respiratory virus protections for high-risk groups, focusing on the cellular modulation of innate immunity. The total debt-to-equity ratio trend on the GURU.Markets chart demonstrates the financial leverage, where the 0.07 mark indicates the current state. The company is currently testing sepsis drugs while awaiting regulatory approval for market entry.

Institutional capital evaluates Revelation Biosciences (REVB) through the lens of debt load and capital structure stability. This metric compares total liabilities to the book value of equity, reflecting the level of financial leverage. By analyzing the trend of the total debt-to-book equity ratio, an investor can see the company's actual dependence on borrowed funds. For Revelation Biosciences (REVB), this is critical, as high clinical trial costs are covered by secondary offerings rather than debt. A low ratio here indicates a liquidity deficit rather than stability.